{"name":"Azienda Ospedaliero-Universitaria di Parma","slug":"azienda-ospedaliero-universitaria-di-parma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"68Ga-exendin-4","genericName":"68Ga-exendin-4","slug":"68ga-exendin-4","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Metformin-Sitagliptin-Empaglifozin-Pioglitazone","genericName":"Metformin-Sitagliptin-Empaglifozin-Pioglitazone","slug":"metformin-sitagliptin-empaglifozin-pioglitazone","indication":"Type 2 diabetes mellitus (combination therapy)","status":"phase_3"}]}],"pipeline":[{"name":"68Ga-exendin-4","genericName":"68Ga-exendin-4","slug":"68ga-exendin-4","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Metformin-Sitagliptin-Empaglifozin-Pioglitazone","genericName":"Metformin-Sitagliptin-Empaglifozin-Pioglitazone","slug":"metformin-sitagliptin-empaglifozin-pioglitazone","phase":"phase_3","mechanism":"This four-drug combination targets multiple pathways in glucose metabolism: metformin reduces hepatic glucose production, sitagliptin enhances incretin signaling, empaglifozin increases urinary glucose excretion, and pioglitazone improves insulin sensitivity.","indications":["Type 2 diabetes mellitus (combination therapy)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBINFZBbHQydGpuTXJ4UTBRTGFiMi01VU5VT3M3cHUwVXJJVkhfdTU3cEZ4S0k3V21SNk9nWWc2bjl4c283dHc4SmJmcDFnSGw5NkVPaUVOSzNYQjJ6QzlN?oc=5","date":"2025-11-07","type":"trial","source":"Nature","summary":"The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial | Leukemia - Nat","headline":"The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term re","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}